DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK) of metformin (a MATE1/2-K probe substrate), midazolam (a CYP3A4 probe substrate), and caffeine (a CYP1A2 probe substrate).
Epistemonikos ID: 6aca544b1ce06f0901b85eddb238d17d5da2d26f
First added on: Oct 15, 2026